Antisense Oligonucleotides for Pompe Disease Splicing Correction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Pompe disease, particularly those with the c.-32 IVS1-13 T>G mutation, face challenges in restoring normal splicing of exon 2 in the acid alpha-glucosidase (GAA) mRNA, leading to inadequate enzyme activity and variable disease progression.
Innovation Solution
The use of antisense oligonucleotides, specifically designed to target and correct the splicing of exon 2 in the GAA pre-mRNA, either as tricyclo-DNA or 2′-O-methyl-RNA, which are administered systemically to ensure inclusion of exon 2 in the mature mRNA, thereby restoring acid alpha-glucosidase activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antisense oligonucleotides are used to correct splicing of exon 2, then enzyme activity is restored, but the complexity of the treatment increases
Solution Approach 1:
The patent uses antisense oligonucleotides as intermediary molecules that bind to specific sequences in the GAA pre-mRNA to correct splicing defects. These oligonucleotides act as mediators between the defective gene and the desired functional outcome, restoring enzyme activity without requiring direct gene modification or complex cellular engineering
Solution Approach 2:
The patent employs chemical modifications of the oligonucleotide backbone (phosphorothioate, methylphosphonate, phosphodithioate) to change the physical and chemical parameters of the therapeutic agent. These parameter changes improve stability, reduce immunogenicity, and enhance tissue penetration while maintaining the splicing correction function
2Adaptability or versatility
If systemic delivery is used to access all affected tissues, then treatment coverage is improved, but the difficulty of delivering the oligonucleotide increases
Solution Approach 1:
The patent systematically modifies the oligonucleotide backbone chemistry to change parameters such as charge, hydrophobicity, and metabolic stability. These parameter changes enable the molecule to withstand systemic circulation, penetrate tissue barriers, and reach target cells throughout the body including skeletal muscle, heart, and liver
Solution Approach 2:
The patent creates composite oligonucleotide structures combining different chemical modifications (e.g., phosphorothioate backbone with 2'-O-methyl ribose) to achieve multiple functions simultaneously: stability in circulation, cellular uptake, nuclear delivery, and splicing correction. This composite approach overcomes the limitations of simple oligonucleotide delivery
3Reliability
If exon 2 inclusion is corrected in patients with c.-32 IVS1-13 T>G mutation, then functional GAA mRNA is produced, but the specificity of the treatment for this mutation is required
Solution Approach 1:
The patent designs oligonucleotides with sequences specifically complementary to the aberrant splicing intermediates created by the c.-32 IVS1-13 T>G mutation. The local quality of the oligonucleotide sequence is tailored to recognize and correct only this specific mutation's splicing defect, ensuring specificity while restoring functional mRNA
Solution Approach 2:
The patent uses oligonucleotides that bind to specific regions of the pre-mRNA involved in the splicing defect caused by the c.-32 IVS1-13 T>G mutation. By targeting only the critical splicing junctions affected by this mutation, the treatment achieves correction with high specificity rather than attempting to address all possible GAA mutations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively rescues the full-length GAA mRNA and enhances enzyme activity in patients with the c.-32 IVS1-13 T>G mutation, demonstrating significant improvement in Pompe disease management by promoting the inclusion of exon 2 during splicing.
Implementation Method 1
a nucleic acid 10 to 50 nucleotides in length, complementary to a nucleotide sequence of the acid alpha-glucosidase (GAA) pre-mRNA
Data Source
AI summary
The invention relates to nucleic acids and methods for restoring acid alpha-glucosidase (GAA) activity in patients with Pompe disease using splice-switching technology.